Cognition Therapeutics Inc. announced the completion of enrollment in its Phase 2 randomized, placebo-controlled START study, evaluating zervimesine (CT1812) in individuals with mild cognitive impairment $(MCI)$ or early Alzheimer's disease. The study reached its target enrollment of 540 participants, with additional patients in the final screening stages. The START study, conducted in collaboration with the Alzheimer's Clinical Trials Consortium, is designed to assess the safety and activity of zervimesine. Approximately 15% of participants are also receiving background therapy with either Leqembi (lecanemab) or Kisunla (donanemab). Topline results are expected after all participants have completed 18 months of treatment. Phase 2 results in mild-to-moderate Alzheimer's disease and dementia with Lewy bodies were presented earlier in 2025 at international conferences and to study investigators.